Leonard Yaffe
Contributor since: 2014
Articles
Healthcare Sector Stock Performance Continues To Improve
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
The Correction In Biopharmaceutical Stocks Is Likely Over
Outlook For 2022: Continued Investment Opportunities Related To COVID-19 Pandemic; Drug Price Legislation Flawed
Moderna: R&D Day Highlights Impressive Pipeline, COVID-19 Vaccine Revenues Appear Longer-Lasting
COVID-19 Vaccines And Booster Shots Will Be Required For Years, Suggesting That Moderna Will Significantly Exceed Projections
Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value Creation
Medical Stocks 2021 Outlook: 2 Strong Tailwinds Should Drive Favorable Performance
Eiger BioPharmaceuticals: Peginterferon Lambda COVID-19 Data Very Positive
Eyenovia: Continued Pipeline Progress, Attractive Valuation
Alpha Pro Tech: Coronavirus Pandemic Should Provide Strong Tailwind Through 2021
Tandem Diabetes Care: Gaining Share In A Growing Market
Coronavirus Pandemic: Regeneron And Eiger BioPharmaceuticals Positioned To Benefit From Opportunity In Treating Early Stage And At-Risk Patients
Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials
AbbVie: Stock Remains Extremely Attractive Despite Recent Price Appreciation
The New Normal Of The Coronavirus Pandemic: Investment Implications
Regeneron: Favorable Performance Of Current Product Portfolio, Impressive Pipeline Bode Well For Growth Over The Next Decade
DURECT Corporation: DUR-928 May Benefit COVID-19 Patients With Acute Organ Injury
Eiger BioPharmaceuticals: Promising COVID-19 Effort With Peginterferon Lambda Just Entering Clinical Trials
Alpha Pro Tech: Face Mask Policies Drive Strong Demand For Its Disposable Protective Apparel
The 'New Normal' Behavior Driven By The Coronavirus Pandemic Will Drive Stock Selection
Stock Market Outlook: Action From Here Likely To Remain Volatile And Frustrating, With Upside Bias
Alpha Pro Tech: The 'New Normal' Resets To A Stronger Sustainable Business
Coronavirus Pandemic Requires Patient Investing And A Focused Portfolio
2020 Outlook For Medical Stocks: Greater Selectivity But Continued Consolidation And Favorable Developments
Hepion Pharmaceuticals And Neoleukin Therapeutics: 2 Micro-Cap Pharmaceutical Stocks Priced For 'Non Success' With Promising Drugs
Cryoport: Cold Chain Is A Hot Business Model
Durect Corporation: DUR-928 Data In Severe Alcoholic Hepatitis To Be Showcased At Upcoming AASLD Meeting
Eyenovia: Promising Pipeline In Underserved Ophthalmic Diseases
Allena Pharmaceuticals: Unique Treatment For Enteric Hyperoxaluria Not Reflected In Valuation
Ardelyx: Attractive Valuation, Upcoming Major Catalysts
AbbVie: Low P/E Multiple, Solid Dividend And Favorable Growth
Medicare Part D Proposed Restructuring Would Be Impactful To Pharmaceutical Companies
Outlook For Healthcare Stocks Remains Favorable
Tandem Diabetes: ADA Presentations Reaffirm Control-IQ Excellent Performance
Tandem Diabetes: Strong Business Trends Should Continue Due To Market Growth And Share Gains
Tandem Diabetes: The Pump Is Primed
The Week That Was In San Francisco: 2019 Should Be A Great Year For Healthcare Stocks
Tandem Diabetes Investor Day: Pumping Out Profits Soon
Tandem Diabetes: Beneath The Numbers, The Story Is More Impressive